Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin

Figure 6

Comparison of CCR7 + CD8+ and effector T cells before and after MSC treatment. PBMCs were stained with anti-CD8 APC-conjugated, anti-CCR7 streptavidin Cy5.5-conjugated, anti-IFN-γ FITC-conjugated, anti-CD28 PE-conjugated, and anti-CD57 FITC-conjugated antibodies. The representative figure for the flow cytometric analysis of CCR7+ CD8+/lymphocytes and CD28-CD57+/CD8+ T cells is shown. “Before” indicates the results at the start of MSC treatment, and “After” indicates the results at 3 months after the final MSC infusion. MSCs: mesenchymal stem cells; PBMCs: peripheral blood mononuclear cells.